



REC'D 03 MAY 1999

WIPO PCT

5

Kongeriget Danmark

Patent application No.: 0112/98

Date of filing: 27 Jaunary 1998

Applicants: Gellerfors, Pär, Lagmannsvägen 13, 181 63
Lindingö, Sweden; Fogh, Jens, Bjergagervej 37,
3540 Lynge, Denmark.

This is to certify the correctness of the following information:

The attached photocopy is a true copy of the following document:

- The specification and claims filed with the application on the filing date indicated above.

By Assignment signed by Gellerfors, Pär and Fogh, Jens on 19 June 1998, all rights, title and interest in and to the invention as claimed and described in the above 0112/98 filed on 27 January 1998 were assigned to HemeBiotech A/S, Bjergagervej 37, 3540 Lynge, Denmark.



Erhvervsministeriet
Patentdirektoratet

TAASTRUP, 23 April 1999



Susanne Kjeldmand
Head of section

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

FIELD OF THE INVENTION

The present invention relates to novel methods of treating and preventing disease caused by absence or deficiency of the activity of enzymes belonging to the heme biosynthetic pathway. More specifically, the invention pertains to methods of alleviating the symptoms of certain porphyrias, notably acute intermittent porphyria.

BACKGROUND OF THE INVENTION

Heme biosynthetic pathway

Heme is a vital molecule for life in all living higher animal species. Heme is involved in such important processes as oxygen transportation (haemoglobin), drug detoxification (cytochrome P450), and electron transfer for the generation of chemical energy (ATP) during oxidative phosphorylation in mitochondria.

Heme is synthesised in eight consecutive enzymatic steps starting with glycine and succinyl-CoA. Sassa S. 1996, Blood Review, 10, 53-58 shows a schematic drawing of the heme biosynthetic pathway indicating that the first enzymatic step (ALA-synthetase) and the last three steps (coproporphyrinogen oxidase, protoporphyrinogen oxidase and ferrochelatase) are located in the mitochondrion whereas, the remaining are cytosolic enzymes.

Important regulation of the heme biosynthetic pathway is delivered by the end product of the metabolic pathway, namely heme, which exerts a negative inhibition on the first rate-limiting enzymatic step (conducted by ALA-synthetase) in the heme biosynthetic pathway. (Strand et al. Proc. Natl. Acad. Sci. 1970, 67, 1315-1320).

Deficiencies in the heme biosynthetic enzymes have been reported leading to a group of diseases collectively called porphyrias.

- 5 A defect in the third enzymatic step leads to acute intermittent porphyria, AIP.

Acute Intermittent Porphyria

- 10 Acute intermittent porphyria (AIP) is an autosomal dominant disorder in man caused by a defect (50% reduction of activity) of the third enzyme in the heme biosynthetic pathway, porphobilinogen deaminase, (also known as porphobilinogen ammonia-lyase (polymerizing)), E.C. 4.3.1.8. (Waldenström J. Acta. Med. Scand. 1937 Suppl. 82.). In the following, this enzyme will be termed "PBGD".
- 15

Clinical manifestation of AIP

- 20 The reduction in enzymatic PBGD activity makes this enzyme the rate limiting step in the heme biosynthetic pathway, with a concomitant increase in urinary and serum levels of delta-aminolevulinic acid (ALA) and porphobilinogen (PBG).
- 25 The clinical manifestation of AIP involves abdominal pain and a variety of neuropsychiatric and circulatory dysfunctions. As a result of the enzymatic block, heme precursors such as porphobilinogen (PBG) and delta-aminolevulinic acid (ALA) are excreted in excess amounts in the urine and stool. In acute attacks, high levels of PBG and ALA are also found in serum. These precursors are normally undetectable in serum in healthy individuals.
- 30

- The neuropsychiatric disturbances observed in these patients are thought to be due to interference of the precursors with the nervous system or due to the lack of heme. For instance, ALA bears a close resemblance to the inhibitory neurotrans-
- 35

mitter 4-aminobutyric acid (GABA) and has been suggested to be a neurotoxin. (Jeans J. et al. American J. of Medical Genetics 1996, 65, 269-273).

5 Abdominal pain is the most frequent symptom in AIP patients and occurs in more than 90% during acute attacks, which will be followed rapidly by the development of peripheral neuropathy with weakness in proximal muscles, loss of pinprick sensation, and paraesthesia. Tachycardia, obstipation or diarrhoea may also be present.

During acute attacks behavioural changes, confusion, seizures, respiratory paralysis, coma and hallucinations may be present.

15 Hypertension is also associated with AIP, with as high as 40% of patients showing sustained hypertension between attacks. An association between chronic renal failure (Yeung L. et al. 1983, Q J. Med 52, 92-98) and AIP as well as hepatocellular carcinoma. (Lithner F. et al. 1984, Acta.Med.Scand. 215, 271-274.), has been reported.

The AIP is a lifelong disease which usually becomes manifest in puberty.

25

Factors precipitating acute attacks.

Most precipitating factors exhibit an association with the first rate-limiting enzyme in the heme biosynthetic pathway through heme, the final product of the pathway. A lowering of the heme concentration will immediately increase the rate of ALA-synthetase. An overproduction of ALA then makes the partially deficient PBGD enzyme (50% activity) now rate-limiting with an accumulation of the heme precursors ALA and PBG.

35 Drugs that induces cytochrome P450 such as barbiturates, estrogens, sulphonamides, progesterone, carbamazepine, and phenytoin can all precipitate acute attacks. (Wetterberg L.

1976, In Doss M. Nowrocki P. eds. Porphyrrias in Human Disease. Reports of the discussion. Matgurg an der Lahn, 191-202).

- 5 The clinical manifestation is more common in women, especially at time of menstruation. Endocrine factors such as synthetic estrogens and progesterone are known precipitating factors. A significant factor is also the lack of sufficient caloric intake. Hence, caloric supplementation during acute
10 attacks reduces clinical symptoms. (Welland F.H. et al. 1964, Metabolism, 13, 232).

Finally, various forms of stress including illness, infections, surgery and alcoholic excess have been shown to lead
15 to precipitation of acute attacks. There are also cases of acute attacks where no precipitating factor can be identified.

Prevalence of AIP

- 20 Prevalence of 0.21% has been reported (Tishler P.V: et al. 1985, Am.J.Psychiatry 142,1430-1436), with as high a prevalence as 1 per 1500 in geographic isolates in northern Sweden (Wetterberg L. 1967, Svenska bokförlaget Nord-
25 stedt, Stockholm). Prevalence up to 200 per 10.000 inhabitants have been reported from northern Finland. (Andersson, Christer, Thesis, 1997, ISBN 91/7191/280/0).

Existing treatment of AIP

- 30 The treatment of AIP as well as of other types of porphyrias such as variegate, hereditary coproporphyria, harderoporphyria, and aminolevulinic acid dehydratase deficiency, are basically the same. Existing therapies for AIP, are all aimed
35 at reducing circulating PBG and ALA by inhibiting the first rate-limiting enzymatic step ALA-synthetase. This inhibition of ALA-synthetase is achieved by increasing circulating heme,

since heme is a negative feed back regulator of ALA-synthetase. Hematin treatment, high caloric intake or inhibition of heme breakdown by Sn-mesoporphyrin administration are the existing therapies today. These therapies have shown limited efficacy.

Treatment between acute attacks involves sufficient caloric intake and avoidance of drugs and immediate treatment of infections.

Patients that experience acute attacks are treated with intravenous carbohydrates usually dextrose (300 g/day) and intravenous hematin (3 - 8 mg/(kg day)).

Treatments with long acting agonistic analogues of LHRH, have been shown to reduce the incidence of pre-menstrual attacks by inhibiting ovulation in AIP patients. Finally, treatments involving heme analogues Sn-mesoporphyrin, which inhibit heme breakdown have also been attempted.

Medical need in AIP

The lack of effective treatment for AIP is well recognised. In a US mortality study in AIP patients requiring hospitalisation it was concluded that the mortality rate was 3.2-fold higher as compared to a matched general population. Suicide was also a major cause of death, occurring at a rate of 370 times that expected in the general population (Jeans J. et al.1996, Am. J. of Medical Genetics 65, 269-273).

Hematin therapy is usually initiated when high caloric intake is not sufficient to alleviate acute attacks. Studies with hematin have been performed but these studies generally used the patients as their own control after the patients did not respond to high carbohydrate treatment. (Mustajoki et al. 1989, Sem. Hematol. 26, 1-9).

The one controlled study with hematin treatment reported, failed to reach statistical significance due to too small a patient number (Herrick A.L. et al 1989, Lancet 1, 1295-1297).

5

In conclusion, there is a definite need for the provision of novel therapeutic/prophylactic methods aimed at these diseases.

10 DISCLOSURE OF THE INVENTION

Levels of ALA and PBG found in urine in patients with symptomatic AIP, are in the range of 1-203 mg/day and 4-782 mg/day, respectively. Normal excretion of ALA and PBG is very low (0-4 mg/day). Important is the observation that these patients also have elevated levels of ALA and PBG in serum. It was shown in a study that AIP patients had significantly elevated levels of ALA (96 μ g %) and PBG (334 μ g %) in serum in connection with acute attacks and that the severity of the attacks were correlated to high levels of ALA and PBG. Hence, it is important to reduce the circulating levels of ALA and PBG in order to eliminate clinical symptoms and to normalize the heme pool.

25 The present inventors present a new therapeutic rational in the treatment of AIP, a rationale using PBGD, preferably recombinant PBGD (rPBGD) in order to reduce circulating high levels of PBG in serum by metabolising (by enzymatic conversion) PBG to hydroxymethylbilane (HMB), which is the normal product of the reaction. This substitution therapy will lead to a normalization of PBG in serum as well as to a normalization of the heme pool. It will also lead to a normalization of ALA in serum, since these heme precursors are in equilibrium with each other. A lowering of serum ALA and PBG is expected to result in a concomitant relief of symptoms. The product of the reaction (HMB) will diffuse back into the

cells and enter the normal heme biosynthetic pathway and will become subsequently metabolized to heme.

Hence, PBGD administered by injections will carry out its normal catalytic function by converting PBG to HMB in serum (extracellularly, not inside the cells), where it normally functions. The new therapeutic idea is based on the assumption that ALA, PBG and HMB permeate cellular membranes or are transported specifically across them. An alternative to this is to administer a form of PBGD which will be able to act intracellularly, either as a consequence of formulation or as consequence of modification of PBGD so as to facilitate its entry into cells from the extracellular compartment.

The observation that AIP patients have large amounts of these heme precursors in the serum supports the idea that PBG does not accumulate intracellularly, but is released from the cells into serum when the intracellular concentration increases due to the PBGD enzymatic block.

The basic new therapeutic concept for AIP is valid for all porphyrias and therefore the invention is in general aimed at treating these diseases by substituting the reduced or missing enzymatic activity characterizing the porphyrias.

Hence, in its broadest aspect, the invention pertains to a method for treatment or prophylaxis of disease caused by deficiency, in a subject, of an enzyme belonging to the heme biosynthetic pathway, the method comprising administering, to the subject, an effective amount of a catalyst which is said enzyme or an enzymatically equivalent part or analogue thereof.

Hence, by the term "catalyst" is herein meant either the relevant enzyme which is substituted as it is, or an enzymatically equivalent part or analogue thereof. One example of an enzymatically equivalent part of the enzyme could be a do-

main or subsequence of the enzyme which includes the necessary catalytic site to enable the domain or subsequence to exert substantially the same enzymatic activity as the full-length enzyme.

5

An example of an enzymatically equivalent analogue of the enzyme could be a fusion protein which includes the catalytic site of the enzyme in a functional form, but it can also be a homologous variant of the enzyme derived from another species. Also, completely synthetic molecules which mimic the specific enzymatic activity of the relevant enzyme would also constitute "enzymatic equivalent analogues".

In essence, the inventive concept is based on the novel idea of substituting the reduced enzymatic activity in the subject simply by administering a catalyst which will "assist" the enzyme which is in deficit. The precise nature, however, of the catalyst is not all-important. What is important is merely that the catalyst can mimic the enzymatic *in vivo* activity of the enzyme.

Previous investigations in treating the porphyrias have suggested gene therapy, thus aiming at introducing genetic material in relevant cells which will then take over the *in vivo* production of the enzyme of interest. The present approach is much more simple but has to the best of the knowledge of the inventors never been suggested, perhaps because difficulties with respect to achieving an intracellular effect on the precursor level has been regarded as an obstacle.

30

The term "the heme biosynthetic pathway" refers to the well-known enzymatic steps (cf. e.g. Sassa S. 1996, Blood Review, 10, 53-58) which leads from glycine and succinyl-CoA to heme, and enzymes belonging to this synthetic pathway are uroporphobilinogen deaminase (PBGD), ALA dehydratase, Uroporphyrinogen-decarboxylase, Coproporphyrinogen oxidase, Coproporphyrinogen

35

oxidise, Protoporphyrinogen oxidase, Uroporphyrinogen III synthase, Ferrochelatase, and Uroporphyrinogen decarboxylase. Hence, in line with the above, a catalyst used according to the invention is such an enzyme or an enzymatically equivalent part or analogue thereof. It should be noted that all of the above-mentioned enzymes have been sequenced, thus allowing recombinant or synthetic production thereof.

The diseases related to reduced activity of these enzymes are acute intermittent porphyria (AIP), ALA deficiency porphyria (ADP), Porphyria cutanea tarda (PCT), Hereditary coproporphyria (HCP), Harderoporphyria (HDP), Variegata porphyria (VP), Congenital erythropoietic porphyria (CEP), Erythropoietic protoporphyria (EPP), and Hepatoerythropoietic porphyria (HEP).

By the term "effective amount" is herein meant a dosage of the catalyst which will supplement the lack of enzymatic activity in a subject suffering from porphyria caused by reduced activity of one of the above-mentioned enzymes. The precise dosage constituting an effective amount will depend on a number of factors such as serum half-life of the catalyst, specific activity of the catalyst etc. but the skilled person will be able to determine the correct dosage in a given case by means of standard methods (for instance starting out with experiments in a suitable animal model so as to determine the correlation between blood concentration and enzymatic activity).

The disease which is the preferred target for the inventive method is AIP, and therefore the catalyst is PBGD or an enzymatically equivalent part or analogue thereof. It is most preferred that the catalyst is a recombinant form of the enzyme belonging to the heme biosynthetic pathway or of the enzymatically equivalent part or analogue thereof, since recombinant production will allow large-scale production which,

with the present means available, does not seem feasible if the enzyme would have to be purified from a native source.

Preferred formulations and dosage forms of the catalyst is exemplified for, but not limited to, PBGD in the detailed description hereinafter, and these formulations also are apparent from the claims. It will be appreciated that these formulations and dosage forms are applicable for all catalysts used according to the invention.

10

One important embodiment of the method of the inventions is one wherein the catalyst, upon administration, exerts at least part of its enzymatic activity in the intracellular compartment. This can e.g. be achieved when the catalyst is an enzymatically equivalent part or analogue of the enzyme, since such variations of the enzyme can be tailored to render them permeate cell membranes. Hence, when the catalyst is a small artificial enzyme or an organic catalyst which can polymerize porphobilinogen to hydroxymethylbilane, it should be possible for the skilled man to introduce relevant side chains which facilitates entry into the intracellular compartment. Alternatively, the catalyst is the enzyme, but formulated in such a manner that it exerts at least part of its enzymatic activity intracellularly upon administration to the subject. This can be achieved by tagging the enzyme with specific carbohydrates or other liver cell specific structures for specific liver uptake, i.e. the enzyme (or analogue) is modified so as to facilitate active transport into e.g. liver cells.

30

Although the above embodiments are interesting, it is believed that the normal, practical embodiment of the invention will involve use of a catalyst which exerts substantially all its enzymatic activity extracellularly in the bloodstream, since it is believed that the metabolic products of the enzymatic conversion of the relevant heme precursor will permeate freely into the intracellular compartment where the remaining

conversions of the heme biosynthetic pathway can take place. Alternatively, the metabolic product may be excreted from the subject via urine and/or faeces at least to some extent.

5 As mentioned above, it is preferred that the catalyst is produced recombinantly, i.e. by a method comprising

- a) introducing, into a suitable vector, a nucleic acid fragment which includes a nucleic acid sequence encoding the catalyst;
- 10 b) transforming a compatible host cell with the vector;
- c) culturing the transformed host cell under conditions facilitating expression of the nucleic acid sequence; and
- d) recovering the expression product from the culture
- 15 and optionally subjecting the expression product to post-translational processing, such as in vitro protein refolding, enzymatic removal of fusion partners, alkylation of amino acid residues, and deglycosylation, so as to obtain the catalyst.

20

For relatively small catalysts (e.g. those constituted mainly of the active site of the enzyme), the catalyst can alternatively be prepared by liquid-phase or solid-phase peptide synthesis.

25

A more detailed explanation of the recombinant production of the model enzyme PBGD is given in the detailed section hereinafter, but as mentioned herein the same considerations apply for all other peptide catalysts of the invention. One of the main advantages of producing the catalyst by recombinant or synthetic means is, that if produced in a non-human cell, the catalyst is free from any other biological material of human origin, thus reducing problems with antigenicity etc.

35 The dosage regimen will normally be comprised of at least one daily dose of the catalyst, (preferably by the intravenous route). Normally 2, 3, 4 or 5 daily dosages will be neces-

sary, but if sustained release compositions are employed, fewer than 1 daily dosage are anticipated.

The daily dosage should be determined on a case by case basis by the skilled practitioner, but as a general rule, the daily dosage will be in the range between 0.01 - 1.0 mg/kg body weight per day of the catalyst. More often the dosage will be in the range of 0.05 - 0.5 mg/kg body weight per day, but it should never be forgotten that precise dosage depends on the dosage form and on the activity of the catalyst as well as on the degree of deficiency of the relevant enzyme.

For PBGD, the daily dosage is about 0.08-0.2 mg per kg body weight per day, and most often 0.1 mg per kg body weight per day will be the dosage of choice. It is believed that comparable dosages will be applicable for the other full-length enzymes.

Finally, as will be appreciated from the above disclosure, the invention is based on the novel idea of providing substitution for the enzymes lacking in activity. To the best of the knowledge of the inventors, therapeutic use of catalysts having such effects have never been suggested before, and therefore the invention also pertains to a catalyst as defined herein for use as a pharmaceutical. Furthermore, use of such catalysts for the preparation of pharmaceutical compositions for treatment of the above-discussed diseases is also part of the invention.

DETAILED DISCLOSURE OF THE INVENTION

The following description of preferred embodiments of the invention will focus on recombinant production of PBGD and formulations and uses thereof. It will be appreciated, however, that all disclosures relating to this polypeptide apply also for the other enzymes mentioned above. Hence, production and use of PBGD only exemplifies the invention, but all other en-

zymes of the heme biosynthetic pathway can be substitute PBGD in the embodiments described hereinafter.

Production of recombinant PBGD

5

As mentioned above, it is preferred to administer recombinant versions of the various enzymes of the heme biosynthetic pathway. In the following will be described recombinant production of one of these enzymes, namely PBGD.

10

The gene for the erythropoietic PBGD, which is located in the human genome in the chromosomal region 11q 24, is composed of 15 exons spanning 10 kb of DNA and is shown in Grandschamp B. et al. 1996. J. of Gastroenerology and Hepatology 11, 1046-15 1052.

The gene coding the erythropoietic PBGD enzyme (344 amino acids) (Raich N. et al 1986, Nucleic. Acid. Res, 14, 5955-5968), will be cloned from a human erythropoietic tissue by 20 reverse transcriptase or amplification by PCR (polymerase chain reaction) of the PBGD coding region.

The gene will be inserted in a plasmid (bacterial: B-G&F-PBGD, yeast: Y-G&F-PBGD, or mammalian: M-G&F-PBGD) and trans- 25 formed into a suitable host cell (a bacterium such as E. coli and B. subtilis, a fungus such as Saccharomyces, or a mammalian cell line, such as CHO cells). The expression of the PBGD gene will be regulated by a promoter which is compatible with the selected host cell.

30

For production in E. coli the PBGD coding sequence can be inserted into a plasmid vector, e.g. pBR322 or PUC.

For yeast production, the PBGD coding sequence can be in- 35 serted into a plasmid vector, for example YEP type, containing 2 u origin for high expression in yeast. YEP plasmids

contain TRP 1 and URA 3 as markers for selective maintenance in trp1-, ura 3-yeast strains.

Alternatively, the PBGD gene can be inserted in bovine papilloma virus vectors BPV for high expression in a murine cell line C-127(Stephens P.E. et. al. Biochem J. 248, 1-11, 1987) or vectors compatible with expression in CHO cells or COS cells.

- 10 For bacterial production: Insert in front of the PBGD coding region a bacterial signal sequence for example an E. coli periplasmic enzyme signal peptide or a signal peptide from a secreted enterotoxin or endotoxin in E. coli, to obtain secretion in E. coli. An ATG sequence at the NH2-terminal end
15 of the rPBGD structural gene for initiation of translation or a short leader sequence with an ATG at the 5'-end for cytoplasmic expression.

- A secretory signal in Saccharomyces, for example alpha-mating factor presequence, can be added in front of the rPBGD structural gene for efficient secretion in yeast.
20

- Similarly, a sequence encoding a mammalian signal peptide can be added for secretion of rPBGD into the culture medium upon expression in for example CHO cells or COS cells.
25

- A bacterial promoter for example the tryptophane (trp) promoter or the lac promoter or alternatively an alkaline phosphatase promoter, should be inserted before the PBGD coding region for efficient transcription in prokaryotes for example E. coli .
30

- A yeast promoter for example 3-phosphoglycerate kinase (PGK) or chelatin or alpha-mating factor should be inserted before the PBGD coding region for efficient transcription in yeast for example Saccharomyces cerevesiae or Saccharomyces pombe.
35

A mammalian promoter for example Metallothionin-1 (MT-1) or Aspartame transcarbamylase or Dihydrofolate reductase (DHFR) should be inserted before the PBGD coding region for efficient transcription in mammalian cell lines for example CHO cells or COS cells.

The bacterial plasmid (B-G&F-PBGD) containing a bacterial promoter, signal peptide or only an ATG sequence in front of the PBGD coding region, and the PBGD coding region and vector sequences from for example pBR322, will be transformed into a bacterial host strain for example E. coli for production of rPBGD.

The yeast plasmid (Y-G&F-PBGD) containing a yeast promoter, signal and/or ATG codon (methionine) in front of the PBGD coding region and a yeast vector containing selectable markers such as URA 3 or TRP 1 will be transformed into the yeast host cell such as *Saccharomyces cerevesiae* or *Saccharomyces pombe* for production of rPBGD.

The mammalian plasmid (M-G&F-PBGD) containing a mammalian promoter for example Metallothionine-1 or Dihydrofolate reductase and a mammalian signal sequence or an ATG codon in front of the PBGD coding region and vector pAT or pSV2 respectively. Plasmid (M-G&F PBGD) will be transfected into a mammalian cell line for example CHO cells, for production of rPBGD.

The E. coli cell containing plasmid (B-G&F-PBGD), will be fermented to stationary phase between 24-48 hours, in a medium containing casein hydrolysate, or yeast extract, glucose, vitamins and salts. pH oxygen will be monitored by electrodes during fermentation. Temperature will be kept at 37 +/- 2 C during the fermentation.

The yeast cell containing the plasmid (Y-G&F-PBGD), will be fermented to late log phase between 20-40 hours in a medium

containing yeast extract, glucose, salts and vitamins. pH and temperature will be monitored by specific electrodes during fermentation. Temperature will be kept at 30+/- 2 C during fermentation.

5

The mammalian cell line containing the plasmid (M-G&F-PBGD) will be fermented in a medium containing , foetal calf serum (or serum free), vitamins, glucose, antibiotics, growth factors. pH and temperature will be monitored continuously during fermentation by specific electrodes.

10

The PBGD enzyme will be purified from the cells after fermentation.

15 rPBGD will recovered from E. coli after fermentation by an extraction procedure involving for example ribipress, sonication, osmotic shock or total solubilization by detergent for example Tween 80, Triton X-100 or Brij. rPBGD will be recovered from fermentation medium after production in yeast or
20 from a total cellular extract using detergents such as Triton X-100, Tween 80 or Brij. rPBGD will be recovered from mammalian culture medium or from a total cellular extract by ion-exchange chromatography or affinity chromatography.

25 rPBGD will be purified from E. coli extract or from yeast medium or total cellular extract or from mammalian culture medium or total mammalian cellular extract by binding to an ion-exchange column for example DEAE-Sephadex or MonoQ-Sephadex and eluted with for example NaCl and Sodium phosphate buffer pH 7-8 or the corresponding potassium salts.
30 Alternatively, rPBGD will be recovered from extracts by binding to an affinity chromatography column for example an anti-PBGD affinity column. rPBGD will be eluted by lowering the pH to 4-2, or a thiol specific affinity column. rPBGD has
35 been "tagged" with thiols residues when a thiol affinity column step is used. Thiols will be removed by a specific enzymatic cleavage step to generate authentic rPBGD.

The ion-exchange or affinity purified rPBGD will be further purified by hydrophobic interaction chromatography on for example, TSK Phenyl 5 PW column or Octyl-Sepharose or Phenyl-Sepharose columns.

5

Binding of rPBGD will be done at high ionic strength for example in 10-50 mM Tris-HCl pH 7-8, 1M NaCl or 10-15 mM Sodium phosphate pH 7-8, 0.5 M MgSO₄ and eluted by lowering the ionic strength for example with 10-50 mM Tris-HCl pH 7-8 or
10 10-50 mM Sodium phosphate pH 7-8.

Three hydrophobic interaction steps will be applied consecutively.

15 rPBGD will be further purified with preparative RP-HPLC for example C12 or C18 matrixes. The rPBGD will be eluted from the column by a gradient of 10-50 mM Sodium phosphate and 1-10% acetonitrile buffer.

20 Formulation of rPBGD will be done by passing the enzyme over a G-100 Sephadex column and eluting it in an isotonic solution for example 0.9%NaCl and 10-50mM Sodium phosphate pH7.0 +/- 0.5 or Sodium phosphate, glycine, mannitol or the corresponding potassium salts.

25

The formulation solution of rPBGD will be sterile filtered and filled aseptically in glass vials and lyophilised. Alternatively, the sterile filtered rPBGD solution will be formulated in for example, lipid vesicles constituting phosphatidylcholine or phosphatidylethanolamine or combinations
30 of these or incorporated into erythrocyte ghosts.

Reconstitution of lyophilised rPBGD will be done in water for injection.

35

Alternatively, rPBGD will be formulated in a sustained release formulation involving a biodegradable microspheres, for

example in polylactic acid., polyglycolic acid or mixtures of these.

Alternatively, rPBGD will be lyophilized in a two-compartment
5 cartridge, where rPBGD will be in the front compartment and water for reconstitution in the rear compartment. This two compartment cartridge will be combined with an injection device to administer either rPBGD by a needle or needle less (by high pressure) device.

10

Alternatively, rPBGD will be formulated in a physiological buffer containing an enhancer for nasal administration.

Alternatively, rPBGD will be formulated in an oral formula-
15 tion containing for example, lipid vesicles (phosphatidylcholine, phosphatidylethanolamine, sphingomyeline) or dextrane microspheres.

Although recombinant production of PBGD is preferred for the
20 treatment of AIP, it can alternatively be produced from human red blood cells.

The production and manufacturing of recombinant PBGD will be done by the following steps.

25

RECOMBINANT PBGD PRODUCTION PROCESS; AN OUTLINE

A: Fermentation

1. Master cell bank
- 30 2. Working cell bank
3. Production of seed culture
4. Fermentation in large fermenter (250 L >)

B. Purification

- 35 1. Cell concentration by filtration/centrifugation
2. Cell disruption
3. Ultrafiltration

4. Chromatography ion exchange, DEAE-Sepharose, MonoQ-Sepharose
5. Hydrophobic interaction chromatography (Octyl/phenyl-Sepharose, TSK Phenyl, 5PW, Phenyl -Sepharose
- 5 6. Chromatography ion exchange (MonoQ)
7. Formulation by Gel filtration Sephadex G-100

C. Manufacturing

1. Sterile filtration
- 10 2. Aseptic filling
3. Lyophilization

TREATMENT OF OTHER PHORPHYRIAS

- 15 In analogy with the new treatment of AIP patients with (recombinant) PBGD, hepatic Porphyrias such as ALA dehydratase ALA deficiency Porphyria (ADP), Porphyria- cutanea tarda (PCT), Hereditary Coproporphyria (HCP) and Variegata Porphyria (VP) can benefit from substitution therapy by rALA de-
- 20 hydratase, rUroporphyrinogen decarboxylase, rCoproporphyrinogen oxidase and rProtoporphyrinogen oxidase, respectively.

- Patients having Erythropoietic Porphyrias such as Congenital erythropoietic Porphyria (CEP) or Erythropoietic protopor-
- 25 phyria (EPP) will benefit from substitution therapy with rUroporphyrinogen III syntetase and rFerrochelataase, respectively.

- Hepatoerythropoietic Porphyrias e.g.. Hepatoerythropoietic
- 30 Porphyrias (HEP) can be treated with rUroporphyrinogen decarboxylase.

- All porphyrias can be treated by the administration of the enzymatic activity lacking or being reduced (normally 50%) in
- 35 any of the eight steps in the heme biosynthetic pathway as described above.

The substitution of the enzymatic activity can be achieved by adding the corresponding recombinant enzyme or other molecules that will provide the missing enzymatic activity.

CLAIMS

1. A method for treatment or prophylaxis of disease caused by deficiency, in a subject, of an enzyme belonging to the heme biosynthetic pathway, the method comprising administering, to the subject, an effective amount of a catalyst which is said enzyme or an enzymatically equivalent part or analogue thereof.
2. A method according to claim 1, wherein the disease is selected from the group consisting of
acute intermittent porphyria (AIP),
ALA deficiency porphyria (ADP),
Porphyria cutanea tarda (PCT),
Hereditary coproporphyria (HCP),
Harderoporphyria (HDP),
Variegata porphyria (VP),
Congenital erythropoietic porphyria (CEP),
Erythropoietic protoporphyria (EPP), and
Hepatoerythropoietic porphyria (HEP).
3. A method according to claim 1 or 2, wherein the catalyst is an enzyme selected from the group consisting of
porphobilinogen deaminase (PBGD)
ALA dehydratase,
Uroporphyrinogen decarboxylase,
Coproporphyrinogen oxidase,
Coproporphyrinogen oxidase,
Protoporphyrinogen oxidase,
Uroporphyrinogen III synthase,
Ferrochelatase, and
Uroporphyrinogen decarboxylase,
or an enzymatically equivalent part or analogue thereof.
4. A method according to any of the preceding claims, wherein the disease is AIP and the enzyme is PBGD or an enzymatically equivalent part or analogue thereof.

5. A method according to any of the preceding claims, wherein the catalyst is a recombinant form of the enzyme belonging to the heme biosynthetic pathway or of the enzymatically equivalent part or analogue thereof.

6. A method according to any of the preceding claims, wherein the catalyst is administered by a route selected from the group consisting of the intravenous route, the intraarterial route, the intracutaneous route, the subcutaneous route, the oral route, the buccal route, the intramuscular route, the anal route, the transdermic route, the intradermal route, and the intratechal route.

7. A method according to any of claims 1-6, wherein the catalyst is formulated in an isotonic solution, such as 0.9% NaCl and 10-50 mM Sodium phosphate pH 7.0 +/- 0.5 or Sodium phosphate, glycine, mannitol or the corresponding potassium salts.

8. A method according to any of claims 1-7, wherein the catalyst is lyophilised.

9. A method according to any of claims 1-8, wherein the catalyst is sterile filtered.

10. A method according to any of claims 1-6, 8 or 9, wherein the catalyst is formulated as lipid vesicles comprising phosphatidylcholine or phosphatidylethanolamine or combinations thereof

11. A method according to any of claims 1-6, 8 or 9, wherein the catalyst is incorporated into erythrocyte ghosts.

12. A method according to any of claims 1-6, 8 or 9, wherein the catalyst is formulated as a sustained release formulation involving biodegradable microspheres, such as microspheres

comprising polylactic acid, polyglycolic acid or mixtures of these.

13. A method according to any of claims 1-9, wherein the catalyst is lyophilized in a two-compartment cartridge, where the catalyst will be in the front compartment and water for reconstitution in the rear compartment.

14. A method according to claim 13, wherein the two compartment cartridge is combined with an injection device to administer the catalyst either by a needle or by a needleless (high pressure) device.

15. A method according to any of claims 1-9, wherein the catalyst is formulated in a physiological buffer containing an enhancer for nasal administration.

16. A method according to any of the preceding claims, wherein the catalyst is formulated as an oral formulation containing lipid vesicles, such as those comprising phosphatidylcholine, phosphatidylethanolamine, or sphingomyeline, or dextrane microspheres.

17. A method according to any of the preceding claims, wherein the catalyst is formulated so as to enhance the half-life thereof in the subject's bloodstream.

18. A method according to claim 17, wherein the catalyst has a polyethylene glycol coating.

19. A method according to claim 17, wherein the catalyst is complexed with a heavy metal.

20. A method according to any of the preceding claims, wherein the catalyst is an enzymatically equivalent part or analogue of the enzyme and exerts at least part of its enzy-

matic activity intracellularly upon administration to the subject.

21. A method according to claim 20, wherein the catalyst is a
5 small artificial enzyme or an organic catalyst which can polymerize porphobilinogen to hydroxymethylbilane

22. A method according to any of claims 1-9, wherein the catalyst is said enzyme formulated in such a manner that it
10 exerts at least part of its enzymatic activity intracellularly upon administration to the subject.

23. A method according to claim 22, wherein the catalyst is tagged with specific carbohydrates or other liver cell specific
15 structures for specific liver uptake.

24. A method according to claims 1-19, wherein the catalyst exerts substantially all its enzymatic activity extracellularly in the bloodstream.
20

25. A method according to claim 24, wherein the enzymatic activity of the catalyst on its relevant heme precursor results in a metabolic product which 1) either moves into the intracellular compartment and is converted further via the remaining steps of the heme biosynthetic pathway or 2) is excreted
25 from the subject via urine and/or faeces.

26. A method according to any of the preceding claims, wherein the catalyst has been prepared by a method comprising
30

- a) introducing, into a suitable vector, a nucleic acid fragment which includes a nucleic acid sequence encoding the catalyst;
- b) transforming a compatible host cell with the vector;
- 35 c) culturing the transformed host cell under conditions facilitating expression of the nucleic acid sequence; and
- d) recovering the expression product from the culture

and optionally subjecting the expression product to post-translational processing, such as in vitro protein refolding, enzymatic removal of fusion partners, alkylation of amino acid residues, and deglycosylation, so as to obtain the catalyst.

27. A method according to any of claims 1-25, wherein the catalyst has been prepared by liquid-phase or solid-phase peptide synthesis.

28. A method according to any of the preceding claims, wherein the catalyst is free from any other biological material of human origin.

29. A method according to any of the preceding claims, wherein the catalyst is administered at least once a day, such as 2, 3, 4, and 5 times daily.

30. A method according to any of the preceding claims wherein the daily dosage is in the range of 0.01 - 1.0 mg/kg body weight per day, such as in the range of 0.05 - 0.5 mg/kg body weight per day.

31. A method according to any of the preceding claims, wherein the daily dosage is about 0.1 mg per kg body weight per day.

32. A catalyst which is an enzyme of the heme biosynthetic pathway or an enzymatically equivalent part or analogue thereof, for use as a medicament.

33. Use of a catalyst which is an enzyme of the heme biosynthetic pathway or an enzymatically equivalent part or analogue thereof for the preparation of a pharmaceutical composition for the treatment or prophylaxis of diseases caused by deficiency of said enzyme.

34. The use according to claim 33, wherein the treatment or prophylaxis is performed according to any of claims 1-31.

This Page Blank (uspto)